Study Assessing Risk Factors for Abdominal Pain in Children With Inflammatory Bowel Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

126 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-10-21

Study Completion Date

2018-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To characterize persistent abdominal pain in children with inflammatory bowel disease (IBD) by examining factors such as disease type, activity and location, psychosocial factors, and genetics.

The investigators hypothesize that by using patient pain and psychological assessments in addition to analysis of blood, stool and colonic biopsies, we can better characterize factors that predispose children and adolescents with IBD to have persistent and/or disproportionate abdominal pain.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Anti-TNF Therapy for Refractory Colitis in Hospitalized Children

NCT02799615

Colitis, Ulcerative Bowel Diseases, Inflammatory

COMPLETED

Improving Medication Adherence in Pediatric Inflammatory Bowel Disease

NCT01536509

Crohn's Disease Ulcerative Colitis Indeterminate Colitis +1 more

COMPLETED NA

Targeted Metabolomics to Decipher Dietary Contributions to Pediatric Inflammatory Bowel Disease (IBD) - Main Study

NCT05014243

Gut Microbiome Inflammation Irritable Bowel Syndrome

UNKNOWN

Improving OutcoMes in the Pediatric to Adult Care Transition in Inflammatory Bowel Disease

NCT02085083

Inflammatory Bowel Disease Crohn Disease Colitis, Ulcerative

COMPLETED NA

Durability and Tolerability of Infliximab in Pediatric Inflammatory Bowel Disease Patients: A 10 Year Single Center Experience

NCT01490528

Pediatric Inflammatory Bowel Disease

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective longitudinal inception cohort pilot study. The study will hopefully provide information about why there is persistent abdominal pain in children with IBD by examining factors such as disease type, activity and location, psychosocial factors, and genetics. Fifty newly diagnosed pediatric IBD patients, age 8-17 years will be enrolled into the study. There will be 2 control groups as well: pain control population: 20 patients with irritable bowel syndrome (IBS) or functional abdominal pain (FAP) diagnosis who have no evidence of bowel inflammation will serve as a pain control population for patients with no active inflammation. To serve as a control population for patients with no abdominal pain or inflammation, the investigators will include 10 patients with no gastrointestinal symptoms, who undergo colonoscopy for various reasons such as painless rectal bleeding, polyp surveillance, etc. The investigators anticipate completing enrollment in 12 months and allowed another 12 months for follow-up.

The study participants will be seen every 3 months for a year and they will have the following procedures/test performed:

1. Standard of care blood and stool samples
2. Pediatric Ulcerative Colitis Activity Index (PUCAI) or Pediatric Crohn's Disease Activity Index (PCDAI)

They will have an endoscopy performed at diagnosis then at 12 months from enrollment.

A magnetic resonance enterography (MRE) will be done at diagnosis.

The following pain and anxiety tests will be performed throughout the study:

Pain:

Pain Severity Duration Scale (PSDS) Pediatric Catastrophizing Scale-Child/Parents (PCS-C/P) Pain Burden Interview (PBI) Adolescent Pediatric Pain Tool (APPT)

Anxiety:

Revised Children's Anxiety and Depression Scale (RCADS-25) Children's Somatization Index (CSI-24) Adult Responses to Children's Symptoms (ARCS)

Blood, rectal biopsies and stool specimens will be obtained throughout various time points of the study to look at hematology, sed rates, C-reactive protein, genomic DNA, colon RNA, stool microbiome and stool calprotectin.

In summary, the investigators will be examining:

1. Relationship between clinical factors and persistent abdominal pain in patients with IBD

1. Disease type
2. Location of disease at diagnosis
3. Extent of disease at diagnosis
4. Markers of inflammation at diagnosis and over the course of follow up
5. Active disease vs. inactive disease over the course of follow up
2. Relationship between psychosocial factors persistent abdominal pain, and remission status, specifically in patients with:

1. Inactive IBD vs. active IBD
2. Inactive IBD vs. IBS/FAP
3. We will compare the parental report to patient report in the above mentioned groups
3. Relationship between gene expression, microbiome, persistent abdominal pain, and remission status, specifically in patients with:

1. Inactive IBD vs. active IBD
2. Inactive IBD vs. IBS/FAP
3. Inactive IBD vs. controls with no abdominal pain

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Inflammatory Bowel Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

IBD w/abdominal pain

Patients with IBD with abdominal pain. Extra colonic biopsies for RNA analysis. If blood and stool samples are collected for standard of care:blood analyzed for both genomic DNA and calprotectin, and stool analyzed for microbiome. If no blood is drawn then a buccal swab done for the genomic DNA analysis and stool analyzed for calprotectin.

Pain questionnaires:

Pain Frequency-Severity-Duration Scale Pain Catastrophizing Scale-Child Version Pain Burden Interview Pediatric Quality of Life Inventory Adolescent Pediatric Pain Tool Anxiety/Depression Questionnaires Revised Children's Anxiety and Depression Scale Children's Somatization Inventory Adult Responses to Children's Symptoms

Genomic DNA

Intervention Type GENETIC

blood draw

RNA analysis

Intervention Type GENETIC

Mucosal Biopsy via colonoscopy

Microbiome

Intervention Type GENETIC

Stool microbiome

Calprotectin

Intervention Type OTHER

stool or blood analysis for calprotectin

Pain questionnaires

Intervention Type OTHER

PSDS PCS-C/P PBI APPT

Anxiety/Depression Questionnaires

Intervention Type OTHER

RCADS-25 CSI-24 ARCS

IBD w/out abdominal pain

Patients with IBD and no abdominal pain. Colonoscopy done for standard of care, extra colonic biopsies for RNA analysis. If blood and stool samples are collected for standard of care:blood analyzed for genomic DNA and calprotectin and stool analyzed for microbiome. If no blood is drawn then a buccal swab for the genomic DNA analysis and stool analyzed for calprotectin.

Pain questionnaires:

Pain Frequency-Severity-Duration Scale Pain Catastrophizing Scale-Child Version Pain Burden Interview Pediatric Quality of Life Inventory Adolescent Pediatric Pain Tool Anxiety/Depression Questionnaires Revised Children's Anxiety and Depression Scale Children's Somatization Inventory Adult Responses to Children's Symptoms

Genomic DNA

Intervention Type GENETIC

blood draw

RNA analysis

Intervention Type GENETIC

Mucosal Biopsy via colonoscopy

Microbiome

Intervention Type GENETIC

Stool microbiome

Calprotectin

Intervention Type OTHER

stool or blood analysis for calprotectin

Pain questionnaires

Intervention Type OTHER

PSDS PCS-C/P PBI APPT

Anxiety/Depression Questionnaires

Intervention Type OTHER

RCADS-25 CSI-24 ARCS

Colonoscopy other reasons no abd pain

Patients who have a colonoscopy for other reasons, rectal bleeding or polyp surveillance, no abdominal pain. Extra colonic biopsies for RNA analysis. If blood and stool samples are collected for standard of care:blood analyzed for genomic DNA and calprotectin and stool analyzed for microbiome. If no blood is drawn then a buccal swab for the genomic DNA analysis and stool analyzed for calprotectin.

Genomic DNA

Intervention Type GENETIC

blood draw

RNA analysis

Intervention Type GENETIC

Mucosal Biopsy via colonoscopy

Microbiome

Intervention Type GENETIC

Stool microbiome

Calprotectin

Intervention Type OTHER

stool or blood analysis for calprotectin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Genomic DNA

blood draw

Intervention Type GENETIC

RNA analysis

Mucosal Biopsy via colonoscopy

Intervention Type GENETIC

Microbiome

Stool microbiome

Intervention Type GENETIC

Calprotectin

stool or blood analysis for calprotectin

Intervention Type OTHER

Pain questionnaires

PSDS PCS-C/P PBI APPT

Intervention Type OTHER

Anxiety/Depression Questionnaires

RCADS-25 CSI-24 ARCS

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 8 years or \< 18 years (achieved 8th birthday but not yet their 18th birthday)
* IBD established by standard criteria
* Anticipated availability for follow up for ≥ 1 year
* Informed consent/assent

Exclusion Criteria

* Prior abdominal surgery unrelated to IBD
* Active gastrointestinal infection at time of diagnosis (e.g., C. difficile)
* Other co-morbidities that contribute to abdominal pain (e.g., Familial Mediterranean Fever, metabolic disease)
* Preexisting chronic pain disorder (e.g., fibromyalgia)

Minimum Eligible Age

8 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No